阿斯利康是8届进博会的"全勤生"，前7届展会累计带来18款全球创新药品。本届进博会上，阿斯利康全 面展示了30多年来引入中国市场的40余款创新药品，并首次展出两款肿瘤领域的全球创新药。苏博科介 绍，得益于中国推进药品审评审批制度改革等利好政策，阿斯利康多款原研新药在中国市场获得加速审 批、快速上市，"展品变商品"进程不断加快。"去年进博会上展出的一款罕见病领域全球首创药物，今 年已在中国获批上市，正惠及更多患者。" "通过进博会平台，我们深切感受到中国政府坚定不移扩大对外开放、积极吸引和利用外资的决心，这 极大增强了全球企业对中国经济发展的信心。"苏博科表示，"阿斯利康将继续坚定投资中国的决心，携 手本土伙伴，为实现'健康中国2030'目标和推动高质量发展贡献更大力量。" "进博会是促进跨行业、跨国界对话的宝贵平台。作为世界上首个以进口为主题的国家级展会，进博会 为各国企业深耕中国市场、深化在华合作提供了重要机遇，也见证了中国在提升科技创新能力、优化营 商环境方面的显著成效。"生物制药企业阿斯利康全球首席执行官苏博科近日在接受本报记者专访时表 示。 （文章来源：人民日报） "进博会不仅是展示成果的舞台，更是联 ...

Core Insights - The eighth China International Import Expo (CIIE) took place from November 5 to 10, showcasing over 2,000 enterprises, marking the largest scale in its history [1] - The theme of this year's expo was "From Global Farms to Chinese Tables," highlighting the journey of food across borders [1] - The event coincided with China's "Weight Management Year," reflecting a shift towards healthier and lighter food options among Chinese consumers [1] Company Highlights - Yihai Kerry Arawana Holdings, a long-time participant, showcased its "Golden Dragon Fish Fengyi Hall" functional products, emphasizing health and safety in food [1][2] - The company introduced plant sterol protein milk and glycerol diester oil, targeting health-conscious consumers and aligning with national health initiatives [2] - Louis Dreyfus Company presented its "Soyadoc" specialty feed protein brand, focusing on enhancing animal nutrition and health through innovative products [3] - Cargill displayed a range of innovative products, including new frying oils and functional ingredients, to meet the diverse health needs of Chinese consumers [4]

Group 1 - Cargill has been operating in China for over 50 years and recognizes the significant potential and development opportunities in the Chinese market, committing to increase investments in the region [1] - At the recent China International Import Expo, Cargill showcased a variety of innovative products, including cooking oils, nutritional food ingredients, syrups, cocoa, and chocolate, aligning with the diverse health needs of Chinese consumers and supporting the "Healthy China 2030" strategy [1] - The launch of the new frying oil, Rongjia Qingzha Oil, represents an upgrade in frying performance and addresses consumer concerns regarding trans fatty acids compared to traditional soybean oil and shortening [1] Group 2 - Cargill has initiated a significant investment project in China, with a total planned investment of approximately $500 million for the relocation of its Nantong grain and oil factory, marking an important milestone in its investment strategy [2] - The second phase of the Cargill Yangjiang FR3 natural ester production base has commenced operations, with a total investment exceeding $8 million for both phases [2] - The company anticipates that the Chinese market will increasingly influence the global bulk commodity market, with Brazil expected to contribute approximately 85% of the global increase in bulk commodity production over the next decade due to rising demand [2]

Core Viewpoint - The article emphasizes the strategic opportunities in China's pharmaceutical and healthcare sector, particularly in the context of the "14th Five-Year Plan" and the upcoming "15th Five-Year Plan," highlighting the importance of health in national development and the need for enhanced public health initiatives [1]. Policy and Strategic Initiatives - The "15th Five-Year Plan" proposes a health-first development strategy, aiming to increase the average life expectancy in China from 79 years in 2024 to around 80 years [1]. - The 8th China International Import Expo (CIIE) showcased cutting-edge technologies and innovative products in the healthcare sector, indicating a strong response from the industry to policy initiatives [1]. Chronic Disease Management - Cardiovascular diseases remain a significant health threat in China, with over 330 million patients, and low awareness and treatment rates for blood lipid management [3]. - Collaborative efforts, such as the "Super Consultation" event by Tencent News and Novartis, aim to address public misconceptions about LDL-C and improve cardiovascular disease management [3]. Innovations in Disease Prevention - GSK is focusing on product innovation and health education to promote the prevention of diseases closely related to chronic conditions, such as shingles, which poses increased risks for patients with cardiovascular diseases [4][5]. - Bayer introduced a new product for chronic constipation management, addressing a prevalent health issue among adults in China [5]. Retail Health Services - The retail sector is crucial in connecting healthcare services with public health, with initiatives to extend health services from hospitals to homes [7]. - Novo Nordisk and the China Pharmaceutical Commerce Association launched a health management standard for obesity in retail pharmacies, aiming to enhance patient support [7][9]. AI in Healthcare - AI technology is increasingly integrated into healthcare, enhancing clinical diagnosis and patient management, as demonstrated by various companies at the CIIE [13]. - The launch of AI-driven platforms, such as Boston Scientific's medical knowledge graph, aims to improve clinical education and decision-making [13][14]. Ecosystem Collaboration - The CIIE serves as a platform for collaboration among healthcare companies, fostering partnerships that enhance innovation and market access [18]. - Companies like Merck and Medtronic are focusing on local partnerships to accelerate the introduction of innovative products in China [19][20]. Conclusion - The healthcare sector in China is undergoing significant transformation driven by policy support, technological advancements, and collaborative efforts among industry players, aiming to improve public health outcomes and enhance the overall healthcare ecosystem [1][18].

Core Viewpoint - The article emphasizes the urgent need for a national initiative to manage weight in response to the alarming rise in obesity rates in China, which has become the country with the highest number of obese individuals globally [4][6]. Group 1: Obesity Statistics and Trends - China's adult obesity population surged from 190 million in 2015 to 230 million in 2024, reflecting a growth rate of over 20% [4]. - The adult obesity rate increased from approximately 14% in 2015 to 16.4% in 2020, with projections indicating it could reach 25% by 2030 if no effective measures are taken [4]. - The number of obese children rose from 18 million to 27 million over the past decade, marking a 50% increase [5]. Group 2: Contributing Factors to Obesity - The article identifies several social factors contributing to the obesity epidemic, including the westernization of diets, increased consumption of high-sugar and high-fat foods, and a sedentary lifestyle with an average daily sitting time of 9 hours [5]. - Urbanization has led to lifestyle changes, with urban male obesity rates surpassing those of females, exacerbated by business culture and workplace stress [5]. Group 3: Economic and Health Implications - The economic burden of obesity-related medical expenses is projected to exceed 300 billion yuan in 2024, accounting for 15% of national healthcare spending, and could rise to 418 billion yuan by 2030 [6]. - A significant percentage (89.1%) of obese individuals suffer from at least one chronic disease, with cardiovascular disease-related deaths among obese individuals exceeding 500,000 annually [6]. Group 4: National Weight Management Initiative - The National Health Commission has launched a three-year "Weight Management Year" initiative from 2024 to 2026, aiming to enhance public awareness and skills in weight management [6][14]. - The initiative seeks to reduce the annual growth rate of obesity by 10% and establish a supportive environment for weight management by 2030 [14]. Group 5: Recommended Weight Management Strategies - Effective weight management is based on the principle of "three parts exercise, seven parts diet," emphasizing the importance of controlling caloric intake as metabolism slows with age [6]. - Practical tips include drinking soup before meals to reduce main course intake, chewing food thoroughly to enhance satiety, and controlling eating speed to prevent overeating [6][7].

Core Insights - The eighth China International Import Expo took place from November 5 to 10, showcasing Zeiss Group's commitment to innovation in optical and vision health with over 60 innovative solutions [1] - Zeiss Optical emphasizes its brand values of innovation, precision, and social responsibility, aiming to enhance lifelong visual health and quality for consumers [1] - The company is addressing the growing concern of myopia among youth in China by developing a comprehensive myopia management solution in collaboration with industry partners [1][2] Group 1: Product Innovations - The newly launched Zeiss Growth Eye Lens offers a dual-patent technology that effectively manages myopia while being widely applicable, utilizing defocus design technology [2] - Clinical trial results indicate that the Growth Eye Lens significantly slows the progression of myopia and eye axis growth, providing a professional management solution for children [2] - Zeiss continues to expand its myopia management product range, including the Zeiss Little Round Lens and orthokeratology lenses, supported by precise optical equipment [2] Group 2: Social Responsibility Initiatives - Zeiss Optical has partnered with the China Youth Development Foundation to launch the "Guarding Big Eyes" public welfare project, aiming to provide professional vision checks and eye care education to more families [2] - The company is committed to enhancing eye health awareness through various initiatives, including a live broadcast focusing on eye health for high-intensity users [3] Group 3: Strategic Collaborations - Zeiss Optical signed an AI strategic cooperation agreement with Tencent Health to explore intelligent eye health management solutions [4] - The company aims to improve the overall level and professionalism of eye care services through the pre-release of the "Expert Consensus on Eye Care Center Construction" [4] - A strategic partnership with Tianjin Eye Hospital was established to enhance service capabilities and explore new service paths through digital solutions [4] Group 4: Future Directions - Zeiss Optical is accelerating its diversified business layout to meet market demands for high-quality lifelong vision health solutions [5] - The company plans to deepen collaboration with various partners to support the "Healthy China 2030" initiative, contributing to national visual health [5]

Core Insights - The Chinese healthcare sector is entering a strategic opportunity period, integrating deeply into the "Healthy China" initiative and the global biopharmaceutical competition landscape [1] - The "14th Five-Year Plan" has set a goal to increase the average life expectancy of the Chinese population from 79 years in 2024 to around 80 years by 2029, requiring multi-faceted efforts for achievement [1] - The 8th China International Import Expo (CIIE) showcased cutting-edge technologies and innovative products in the healthcare sector, emphasizing the importance of high-quality development in the pharmaceutical and medical device industries [1] Policy and Strategic Initiatives - The "15th Five-Year Plan" emphasizes a health-first development strategy, aiming to enhance public health and healthcare services [1] - The National Health Commission aims to improve public awareness and management of chronic diseases, particularly cardiovascular diseases, which affect over 330 million people in China [2][3] Disease Prevention and Management - Cardiovascular diseases remain a significant health threat, with a focus on improving public knowledge about blood lipid management to combat related health issues [2] - GSK is promoting a comprehensive management model that integrates chronic disease prevention, including shingles, which poses increased risks for patients with cardiovascular conditions [3][4] Retail Health Services - The retail sector is crucial in connecting healthcare services with public health, with initiatives to extend health services from hospitals to homes [5][6] - Novo Nordisk and other companies are collaborating with retail pharmacies to establish standardized obesity management services, addressing the rising obesity rates in China [5][6] AI in Healthcare - AI technology is increasingly being integrated into healthcare, enhancing clinical diagnosis, medical education, and consumer health management [8][9] - Companies like Philips and Boston Scientific are leveraging AI to improve healthcare delivery and patient outcomes, with significant acceptance among healthcare professionals and patients [11] Ecosystem Collaboration - The CIIE serves as a platform for collaboration among global and local companies, fostering innovation and resource sharing in the healthcare sector [12][13] - Bayer and other companies are utilizing the expo to introduce innovative medical products and enhance local partnerships, aiming to improve healthcare accessibility in China [12][13] Localized Innovation - Merck and Medtronic are focusing on local partnerships to accelerate the introduction of innovative healthcare solutions in China, reflecting the country's growing market potential [13][14] - The "Marco Polo Plan 3.0" by the Cassi Group aims to enhance collaboration across various sectors, promoting medical innovation and accessibility [14][15]

Core Insights - The eighth China International Import Expo (CIIE) showcased significant developments in the pharmaceutical and health sectors, with JD Health forming strategic partnerships with various international brands to enhance health management services [1][3][4] Group 1: Strategic Collaborations - JD Health has established or deepened collaborations with major pharmaceutical and healthcare brands such as Eli Lilly, Novo Nordisk, Bayer, and AstraZeneca, focusing on chronic disease management and women's health [1] - The company has successfully launched new products on its platform, including innovative drugs and nutritional supplements, leveraging its extensive user base and data analytics capabilities to enhance market reach [3][4] Group 2: Supply Chain and Digital Capabilities - JD Health's "super pharmaceutical supply chain" supports efficient distribution and quality assurance of imported products, while also providing professional medical consultations through online and offline channels [1] - The rapid launch of new drugs, such as the targeted therapy for lung cancer, demonstrates JD Health's robust supply chain and digital capabilities, allowing for quick market entry and patient access [3] Group 3: Chronic Disease Management - Chronic diseases pose a significant health threat in China, with over 80% of deaths attributed to major chronic conditions, prompting a national strategy for chronic disease management [6] - JD Health's collaboration with AstraZeneca focuses on managing chronic diseases, providing patients with accessible home health management solutions [6][7] Group 4: AI and Technology Integration - The integration of AI technology in chronic disease management is a key focus, with JD Health collaborating with companies like Omron and Abbott to enhance health data connectivity and create a comprehensive smart health management ecosystem [8] - JD Health has developed various AI-driven services, including virtual doctors and nutritionists, to support patient care and health monitoring [7][8] Group 5: Ecosystem Development - The CIIE has evolved into a hub for global health ecosystem collaboration, with JD Health facilitating a shift from product-focused interactions to comprehensive value chain partnerships [10][11] - By offering a unified platform for pharmaceutical companies, JD Health reduces the complexity and costs associated with market entry, enabling efficient access to both online and offline markets [11]

Core Insights - Sonova made its debut at the 8th China International Import Expo, showcasing a comprehensive range of innovative hearing health solutions, including the Asia premiere of the Phonak AI hearing aids and MRI-compatible cochlear implant technology [1][2] Group 1: Commitment to the Chinese Market - Sonova emphasizes its commitment to deepening its presence in the Chinese market, focusing on hearing health as a critical aspect of public health, especially in light of the "Healthy China 2030" strategy [2][6] - The company has established a complete ecosystem in China that encompasses research and development, production, and service, aiming to provide a full lifecycle hearing health management solution [2][3] Group 2: Innovative Solutions and Product Offerings - At the expo, Sonova presented four key segments: hearing devices, cochlear implants, hearing care services, and consumer hearing products, showcasing its systematic innovation capabilities [3][4] - The Phonak Audeo Paradise AI hearing aids, featuring advanced dual-chip architecture, were highlighted as a key product, enhancing the listening experience through sophisticated algorithms [3][4] - The exhibition also included the AB Ultra 3D cochlear implant, which is compatible with 3.0T MRI technology, ensuring safer clinical procedures for patients [3] Group 3: Strategic Partnerships - Sonova signed a strategic cooperation memorandum with Shanghai Pharmaceuticals, aiming to enhance the hearing health service system and accelerate the delivery of innovative solutions to Chinese patients [1][6] - The partnership is expected to leverage synergies in the hearing health and cochlear implant sectors, contributing to a healthier ecosystem for hearing health in China [6]

Core Insights - The launch of the "Pharmaceutical Insurance Ecological Alliance" by Ping An Good Doctor and Roche Pharmaceuticals China aims to enhance health management services covering the entire cycle from prevention to rehabilitation, improving patient access to innovative drugs and payment flexibility [1][5]. Industry Overview - The financial and healthcare sectors are projected to be the largest and fastest-growing industries in China, driven by increasing household wealth and a growing willingness to pay for health management [2]. - Despite the growth, China's per capita healthcare spending remains significantly lower than that of developed countries, highlighting a potential for expansion in healthcare services [2]. - The aging population in China is leading to a surge in demand for elderly care services, further emphasizing the need for enhanced healthcare solutions [2]. Company Developments - Ping An Good Doctor is leveraging technology to shift from passive treatment to proactive health management, providing comprehensive health services throughout the disease cycle [2][3]. - The company is enhancing its online and offline service capabilities while accelerating the integration of AI technology across its healthcare and elderly care services [3]. - The accuracy of complex disease treatment plans has improved to nearly 90% due to advancements in AI and data integration, significantly enhancing patient experience [3]. Strategic Partnerships - The collaboration between Ping An Good Doctor and Roche Pharmaceuticals China in areas such as innovative flu treatments and oncology drugs is set to deepen, focusing on developing comprehensive digital health management solutions [5]. - This partnership is not only a business collaboration but also aligns with the "Healthy China 2030" strategy, aiming to implement health initiatives on a broader scale [5].